ZA200800376B - Nanoparticulate megestrol formulations - Google Patents
Nanoparticulate megestrol formulationsInfo
- Publication number
- ZA200800376B ZA200800376B ZA200800376A ZA200800376A ZA200800376B ZA 200800376 B ZA200800376 B ZA 200800376B ZA 200800376 A ZA200800376 A ZA 200800376A ZA 200800376 A ZA200800376 A ZA 200800376A ZA 200800376 B ZA200800376 B ZA 200800376B
- Authority
- ZA
- South Africa
- Prior art keywords
- nanoparticulate megestrol
- megestrol formulations
- formulations
- nanoparticulate
- megestrol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69312705P | 2005-06-22 | 2005-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200800376B true ZA200800376B (en) | 2009-03-25 |
Family
ID=37595838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200800376A ZA200800376B (en) | 2005-06-22 | 2008-01-11 | Nanoparticulate megestrol formulations |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1901713A2 (en) |
| JP (1) | JP2008546796A (en) |
| KR (1) | KR20080024213A (en) |
| CN (1) | CN101242810A (en) |
| AU (1) | AU2006262144A1 (en) |
| BR (1) | BRPI0612665A2 (en) |
| CA (1) | CA2613466A1 (en) |
| EA (1) | EA200800099A1 (en) |
| IL (1) | IL188322A0 (en) |
| MX (1) | MX2008000396A (en) |
| NO (1) | NO20080403L (en) |
| WO (1) | WO2007002315A2 (en) |
| ZA (1) | ZA200800376B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105147605B (en) * | 2015-06-24 | 2019-04-19 | 中国人民解放军军事医学科学院毒物药物研究所 | Progesterone nano-composition and preparation method thereof |
| CN105687027A (en) * | 2016-01-26 | 2016-06-22 | 中国科学院生物物理研究所 | Alcohol-free amino acid type rinse-free foam washing solution |
| CN105769763A (en) * | 2016-05-25 | 2016-07-20 | 西安德天药业股份有限公司 | Megestrol acetate nanosuspension and preparation method and application thereof |
| CN108309933A (en) * | 2018-03-19 | 2018-07-24 | 青岛国海生物制药有限公司 | A kind of oral megestrol acetate nanosuspension and preparation method thereof |
| CN108409821A (en) * | 2018-03-19 | 2018-08-17 | 青岛国海生物制药有限公司 | A kind of preparation method and megestrol acetate of megestrol acetate nanocrystal |
| CN112891309B (en) * | 2019-11-19 | 2022-07-26 | 北京化工大学 | Megestrol acetate nano dry suspension and preparation method thereof |
| CN111643463A (en) * | 2020-07-08 | 2020-09-11 | 西安远大德天药业股份有限公司 | Megestrol acetate dispersible tablet and preparation method thereof |
| CN111930838B (en) * | 2020-07-23 | 2023-05-16 | 金陵科技学院 | Time-oriented distributed archive management method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1227626B (en) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | SUPPORTED DRUGS WITH INCREASED DISSOLUTION SPEED AND PROCEDURE FOR THEIR PREPARATION |
| US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
| AU2003230885A1 (en) * | 2002-04-12 | 2003-10-27 | Elan Pharma International Ltd. | Nanoparticulate megestrol formulations |
| CA2544627A1 (en) * | 2003-11-05 | 2005-05-19 | Elan Pharma International Ltd. | Nanoparticulate compositions having a peptide as a surface stabilizer |
-
2006
- 2006-06-22 BR BRPI0612665-0A patent/BRPI0612665A2/en not_active IP Right Cessation
- 2006-06-22 CN CNA2006800304246A patent/CN101242810A/en active Pending
- 2006-06-22 EA EA200800099A patent/EA200800099A1/en unknown
- 2006-06-22 JP JP2008518396A patent/JP2008546796A/en active Pending
- 2006-06-22 AU AU2006262144A patent/AU2006262144A1/en not_active Abandoned
- 2006-06-22 MX MX2008000396A patent/MX2008000396A/en not_active Application Discontinuation
- 2006-06-22 CA CA002613466A patent/CA2613466A1/en not_active Abandoned
- 2006-06-22 KR KR1020087001652A patent/KR20080024213A/en not_active Application Discontinuation
- 2006-06-22 EP EP06773791A patent/EP1901713A2/en not_active Withdrawn
- 2006-06-22 WO PCT/US2006/024349 patent/WO2007002315A2/en active Application Filing
-
2007
- 2007-12-20 IL IL188322A patent/IL188322A0/en unknown
-
2008
- 2008-01-11 ZA ZA200800376A patent/ZA200800376B/en unknown
- 2008-01-21 NO NO20080403A patent/NO20080403L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IL188322A0 (en) | 2008-04-13 |
| MX2008000396A (en) | 2009-02-23 |
| WO2007002315A2 (en) | 2007-01-04 |
| JP2008546796A (en) | 2008-12-25 |
| KR20080024213A (en) | 2008-03-17 |
| WO2007002315A3 (en) | 2007-04-05 |
| AU2006262144A1 (en) | 2007-01-04 |
| BRPI0612665A2 (en) | 2010-11-30 |
| CN101242810A (en) | 2008-08-13 |
| EA200800099A1 (en) | 2008-06-30 |
| CA2613466A1 (en) | 2007-01-04 |
| NO20080403L (en) | 2008-03-19 |
| EP1901713A2 (en) | 2008-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2424581B (en) | Formulations | |
| IL187258A0 (en) | Nanoparticulate clopidogrel formulations | |
| ZA200705384B (en) | Nanoparticulate candesartan formulations | |
| IL187842A0 (en) | Nanoparticulate acetaminophen formulations | |
| EP1909584A4 (en) | Prenylflavonoid formulations | |
| IL188733A0 (en) | Immunoconjugate formulations | |
| IL186609A0 (en) | Nanoparticulate quinazoline derivative formulations | |
| IL185773A0 (en) | Formulations | |
| EP1861104A4 (en) | Improved gacyclidine formulations | |
| EP1951693A4 (en) | Solid formulations | |
| GB0503359D0 (en) | Insecticidal composition | |
| ZA200800376B (en) | Nanoparticulate megestrol formulations | |
| GB2424585B (en) | Speculum | |
| IL192149A0 (en) | Stable s-nitrosothiol formulations | |
| ZA200800365B (en) | Substituted tetrahydroqulnolines | |
| IL187128A0 (en) | Stable nanoparticle formulations | |
| ZA200800146B (en) | Immunoconjugate formulations | |
| GB2443771B (en) | Speculum | |
| GB0518878D0 (en) | Formulations | |
| GB0520388D0 (en) | Formulations | |
| GB0522917D0 (en) | Formulations | |
| GB0526322D0 (en) | Formulations | |
| GB0522828D0 (en) | Novel formulations | |
| GB0500912D0 (en) | Novel formulations | |
| GB0500913D0 (en) | Novel formulations |